Login
Lite Strategy, Inc. logo

Lite Strategy, Inc.

litestrategy.com

What Do They Do?

Holds Litecoin tokens as a reserve asset and writes covered call options on some holdings, while developing drug candidates for nononcologic diseases and assessing cancer drugs for potential licensing or sale.

Do Revenues Turn Into Profits?

No. It lost $71.2M in FY2026.

Operating income, FY2026
−24935% of revenue
▼ −281% (Loss) vs FY2025 (−$17.5M)
Net income, FY2026
−26648% of revenue
▼ −346% (Loss) vs FY2025 (−$15.9M)

How Are They Changing?

Since the FY2026 annual report
Latest quarter: Q1 FY2027, the three months to Sep 30, 2026
Net income
▲ Turned profitable
vs −$3.6M in Q1 FY2026

From cancer drug development to a Litecoin treasury The earlier report described a clinical-stage company developing cancer therapies. The latest report centers on holding Litecoin as a reserve asset, while pursuing pre-clinical work in nononcologic diseases and assessing drug candidates for licensing or sale.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support